Benjamin F. Edwards & Company Inc. Buys 221,078 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Benjamin F. Edwards & Company Inc. increased its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 1,606.9% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 234,836 shares of the company’s stock after purchasing an additional 221,078 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Ginkgo Bioworks were worth $79,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Paloma Partners Management Co bought a new position in Ginkgo Bioworks in the first quarter worth approximately $28,000. First Trust Direct Indexing L.P. bought a new position in Ginkgo Bioworks in the first quarter worth approximately $35,000. Russell Investments Group Ltd. raised its stake in Ginkgo Bioworks by 9,440.6% in the first quarter. Russell Investments Group Ltd. now owns 31,961 shares of the company’s stock worth $37,000 after buying an additional 31,626 shares in the last quarter. Smith Salley Wealth Management raised its stake in Ginkgo Bioworks by 125.0% in the first quarter. Smith Salley Wealth Management now owns 54,000 shares of the company’s stock worth $63,000 after buying an additional 30,000 shares in the last quarter. Finally, Capstone Investment Advisors LLC bought a new position in Ginkgo Bioworks in the first quarter worth approximately $147,000. Institutional investors own 78.63% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on DNA shares. BTIG Research boosted their price objective on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a “sell” rating in a research note on Friday, August 23rd. The Goldman Sachs Group cut their price target on shares of Ginkgo Bioworks from $0.02 to $0.01 and set a “sell” rating on the stock in a report on Tuesday, July 9th. Finally, TD Cowen lifted their price target on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, September 20th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $3.42.

Ginkgo Bioworks Stock Performance

NYSE DNA opened at $8.09 on Friday. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $5.26 and a 12-month high of $75.20. The firm has a market capitalization of $449.64 million, a price-to-earnings ratio of -18.39 and a beta of 1.06.

Ginkgo Bioworks (NYSE:DNA) last released its earnings results on Thursday, August 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). Ginkgo Bioworks had a negative return on equity of 63.09% and a negative net margin of 486.98%. The firm had revenue of $56.21 million for the quarter, compared to the consensus estimate of $41.46 million. Sell-side analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -12.6 EPS for the current year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.